AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which ...

The deal with China’s CSPC Pharmaceuticals, focused on AI-driven research, aims to advance the discovery and development of ...

AstraZeneca has signed a research agreement worth more than $5 billion with Chinese drugmaker CSPC Pharmaceutical Group, the ...

Under terms of the deal, CSPC will receive $110 million upfront, with potential milestone payments reaching up to $5.22 ...

13/06/2025 13:27 {Hot Stocks}CSPC PHARMA(01093) quoted at HK$8.59, down 5.1% 13/06/2025 10:07 {Hot Stocks}CSPC PHARMA(01093) quoted at HK$8.78, down 3% 12/06/2025 13:18 {Hot Stocks}2 listed firms see ...

US chemical output slows, National Resilience consolidates operations, AstraZeneca partners with a Chinese firm, and more ...

The drug licensing talks cover the development, production and sale of a targeted cancer therapy and other CSPC Pharma ...

Find insight on Regis Healthcare, CSPC Pharmaceutical and more in the latest Market Talks covering the health care sector.

AstraZeneca (AZ) and CSPC Pharmaceuticals Group have entered into a partnership worth up to $5.3bn to develop therapies for ...

CSPC will use its artificial-intelligence-driven, dual-engine efficient drug discovery platform to analyze the binding ...

Friday’s deal with CSPC fits neatly within AstraZeneca’s business development strategy of upping investments in AI and in ...

The announcement builds on AZ's announcement earlier this year that it will invest $2.5 billion in an R&D facility in China, ...